No Data
No Data
Brands that moved the day before part 2 Tohokushinsha, Nihon Yamamura Glass, Sumiseki HD, etc.
<コード>Stock name closing price on the 20th ⇒ compared to the previous day ACCESS <4813> 1572-94 No materials were found in particular, so supply and demand factors are central. Meiko <6787> 6390 -340 Last weekend was drastically higher due to the fair value increase of Ichiyoshi Securities. Micronics Japan <6871> 6660-280 semiconductor stocks are sluggish while stocks are strong, but are credit supply and demand aspects affected? Mitsui Matsushima HD <1518> from the beginning of 5000-130, the stock price was drastically high, and profit-taking sales had an advantage. Ee
Santen Pharmaceutical Intends to Buy Back and Cancel up to 38 Billion Yen Worth of Shares
Santen Pharmaceutical (TYO:4536) intends to acquire up to 21.11 million shares worth 38 billion yen from May 10 to Nov. 6 through trading on the Tokyo stock exchange (including off-floor trading), acc
Fuji HD, Rinnai, etc. (added) Rating
Upgrade-Bullish Code | Stock Name | Securities Company | Conventional | After Change |------|------------|------------|------------|---------|<9229>|SunWells |Nomura | “Neutral” | “Buy” |<9434>|SoftBank | Germany | “Hold” | “Buy” |Target Stock Price Change Code
Ajinomoto and others announced stock buybacks on 5/9
The stocks that announced their share acquisition quota settings on 5/9 (Thursday) are as follows <2802>Ajinomoto 12.5 million shares (2.4%) 50 billion yen (24/5/10-24/8/30) <4536>Santenyaku 21.11 million shares (5.8%) 38 billion yen (24/5/10-24/11/6) <5021>Cosmoene HD 3.5 million shares (4.0%) 23 billion yen (24/5/10-25/3/31) <8282>ke
SoftBank's 24/3 operating profit down 17.4% to 876 billion yen, 25/3 forecast 2.7% increase to 900 billion yen
The financial results for the fiscal year ending 2024/3 announced by SoftBank <9434> were sales of 6.84 billion yen, up 2.9% from the previous fiscal year, and operating profit of 876 billion 68 billion yen, down 17.4% from the same period. As for the financial results for the fiscal year ending 2025/3, we plan that sales will increase 1.9% from the previous fiscal year to 6.2 trillion yen, and operating profit will increase 2.7% to 900 billion yen. Consumer businesses, etc., including the main mobile, are expected to grow. Sales of terminals will increase, and profit will increase as sales fees decrease.
Santen Pharmaceutical Co., Ltd. Reports FY Results
No Data